Sat, Nov 22, 2014, 11:40 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Sunesis Pharmaceuticals, Inc. Message Board

tony_montello2003 53 posts  |  Last Activity: Nov 14, 2014 2:09 PM Member since: Nov 17, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Once the license application is approved, than OCATA can begin process to obtain payments from health systems and health insurers in countries treatment is to be used. In Europe this payment or reimbursement will take place country by country. OCATA will be a revenue generating company in 2015 and I am truly appalled by the manipulation of PPS after company revealed this information on a ASM slide yesterday. OCATA pipeline line can generate Billion in revenues in coming years and the PPS action does not reflect any of that...
    Let it be written,
    Things will change dramatically very soon,
    Dr. Tony Montello.

    Sentiment: Strong Buy

  • tony_montello2003 tony_montello2003 Nov 14, 2014 1:37 AM Flag

    Go OCATA, Time to change medical history one cure at a time!
    Let it be written,
    Dr. Tony Montello holding strong to OCAT

    Sentiment: Strong Buy

  • tony_montello2003 tony_montello2003 Nov 10, 2014 7:59 PM Flag

    Piper Analyst Mr. Ted Tenthoff called REGN buy at $14.00 several years ago!
    Let it be written,
    Big Money is coming here, my baby is about to grow up,
    Dr. Tony Montello just left the building.)

    Sentiment: Strong Buy

  • tony_montello2003 tony_montello2003 Nov 10, 2014 7:36 PM Flag

    Shorts are F****** Mr. Ted Tenthoff is about to take you guys to the woodshed, sleep well tonight.) NOT
    Let it be written,
    Dr. Tony Montello.

    Sentiment: Strong Buy

  • Reply to

    we can be fast track

    by nmiamisam Nov 10, 2014 6:31 PM
    tony_montello2003 tony_montello2003 Nov 10, 2014 7:14 PM Flag

    Excellent post announcement of early access UK for SMD after OCATA uplist on NASDAQ!
    Let it be written,
    Dr. Tony Montello.

    Sentiment: Strong Buy

  • PPS target coming. Wotton was at the top of his game. I can't see anyone debating this. He was not at all subtle in his display of confidence of what we own and he took a play right out of my playbook making comparisons with Regeneron. That is exactly what he needed to do. This is why I remain resolute in my investment. He will relentlessly make institutional investors equate our company to where Regeneron was at our stage and what they have grown into. He was spot on, and this will be his battle cry. What we have will easily surpass Regeneron simply by doing the numbers, and there is no way he will sell the company for less than several Billion, or partner for peanuts.
    The pathway is SMD will be a pivotal trial in the UK, early approval, then off the shelf. PW said it several different ways, but the Lancet payoff was immense for Ocata. It elevated recognition by physicians, patients (huge), marketing partners, institutional investors for sources of capital, and over 40 articles written by the media. He slipped another subtle hint in about platelets and LaRue joining Ocata at just the right time.
    So all the "players" trading the stock. Do you still think PW is going raise a bunch of cash at these levels? It sure didn't sound like it to me from Ted. As a matter of fact, he mentioned 20MM of runway left with our current source of Lincoln. Meaning, he will do it at a more opportune time IMO. I was very happy with this decision, because it may mean platelets could be partnered with some non dilutive funding, or he looking for more strategic timing. He also CLEARLY STATED these shares will be used to fund the company for MANY YEARS. This was a great call, and he is bringing transparency to shareholders with a roadmap, something we never heard before. There is strong leadership, interest in the company without question, we are leaps ahead of any other regenerative medicine company, the first to document definitive long term efficacy holding and safety for over 3 years!

    Sentiment: Strong Buy

  • Valued" Mr. Franey article gives a very accurate picture of where ACTC is today, and where OCATA will be in future. Excellent Article, Great Job.
    Let it be written,
    Dr. Tony Montello

    Sentiment: Strong Buy

  • in multiple brokerage accounts to create fear and steal shares from long term holders. ESEKLA touted his 7 step process for almost a year than does a 360 and throws in the towel on the EVE of biggest peer reviewed data release in medical history for ACTC AMD/SMD MA09 theraphis which showed 17 out of 18 patients progression of the disease halted and 10 patients with visual acuity gains. It took doctors and scientists over 10 months to put this peer review article together and it took ESEKLA 10 seconds to discredit the entire study. ESEKLA timed his bash article on the eve of data release with market tanking 200 points to create a false premise to mislead ACTC investors. SEC is looking in to these 1 share trades following the data release all the way today to 11/5/2014 where hundreds of 1 shares were sold to create panic selling in ACTC shares. ESEKLA, EX Con from NY JMY and ex con from Jersey Douglas Dallam teamed up to create this panic selling in ACTC shares, JMY made up lies with 0 scientific knowledge of the Science to discredit ACTC peer reviewed Journal and went as far as to promote STEM cell AMD therapy which uses cells from aborted fetus and showed 0 efficacy in there results presented to date. STEM lead investigator has filed a law suit claiming that STEM therapy for AMD can cause deaths in patients because of the nature of cells in use. DD is just a enforcer of these 2 ESEKLA and JMY and create fear mongering by hogging up 90% of the responses on there articles and I think he is partially #$%$.
    Let it be written,
    There is a special place in hell for ESEKLA JMY DD trying to bring a company down that is trying to bring life saving therapies for patients,
    Dr. Tony Montello.

    Sentiment: Strong Buy

  • tony_montello2003 tony_montello2003 Nov 4, 2014 9:22 PM Flag

    ACTC rebirth as OCATA Thetapeutics coming to a NASDAQ near you in matter of days!
    Let the OCATA Kraken rise to cure all,
    Dr. Tony Montello is here to stay.

    Sentiment: Strong Buy

  • tony_montello2003 tony_montello2003 Nov 3, 2014 8:12 PM Flag

    Nichols,
    Joke is an understatement, JMY stooped to a very low level to make a dollar on back of people suffering from very serious diseases. JMY, there is a special place in hell for you, enjoy your loot for now!
    Let it be written,
    Dr. Tony Montello

    Sentiment: Strong Buy

  • in the low 6's last time before ACTC become OCATA, hold on to your shares tight because ACTC has a big surprise to burry these shorts alive once and for all. JMY and Esekla are bottom feeders that will have a special place in hell for shorting a small company that is trying to bring cures to those afflicted. Seeking Alpha is garbage blog that just got booted by yahoo feed and is on chopping block with Google too as there posts are full of lies and deceit. Hold on tight to your shares because if you blink you will be sidelined out of the greatest opportunity in medical history aka wall street history!
    Let it be written,
    Dr. Tony Montello just left the building.

    Sentiment: Strong Buy

  • tony_montello2003 tony_montello2003 Nov 1, 2014 1:24 AM Flag

    part 2.
    4. Once the price has been set, the shares must be allocated among the investors. The bankers try to allocate in such a way that they don’t quite satisfy the demand of the most interested buyers. This is intended to provide incentive to the under-allocated investor to fill out her position by buying in the aftermarket.
    Finally, as we are all aware that the ASM will be held at Proctor Goodwin ACTC/OCATA law firm November 12, 2014 the meeting location is the best harbinger of what is to follow is a text book RE-IPO with flawless execution. Say less do more, OCATA opens on NASDAQ $16.00, closes $32.00
    Let it be written,
    Dr. Tony Montello Just left the building best of luck all longs.

    Sentiment: Strong Buy

  • Excitement is building in advance to OCATA RE-IPO, PPS and ACTC volume is not reflecting much because everybody is in wait and see mode but those waiting on the sidelines will be left in dust the days and weeks following the Re-IPO. Here is my step by step description of the events folding behind the scenes: I like to voluntarily put a disclaimer before I put my hypothesis out that I own 3% of the outstanding ACTC shares.
    1. As we are all aware that Dr. Paul Wotton in a sec filing a few months back was named to the pricing committee. Pricing committees are often comprised of the company’s CEO, CFO and typically at least one non-management member of the board who has experience in IPOs. The managing underwriter is the investment bank receiving top billing during the RE-IPO; its name is displayed on the top left of the list of bankers on the prospectus cover.
    2. How is the RE-IPO price set: This is # 1 question on all boards right now:
    As we are aware by Fly On the Wall PR last Friday after hours that ACTC management is in meeting with Jeffries as a lead:
    At this meeting, the investment bankers share all the information they have collected on the demand for the offering. The CEO and CFO typically have spent the prior 2 ½ weeks engaging in one-on-one meetings with up to 60 institutional investors. The sales team from the investment bank collects the number of shares each institutional portfolio manager would like to buy at particular prices. Based on this information the “syndicate manager” or “capital markets desk manager” of the lead investment bank recommends a price at which the company’s stock should be sold.
    3.Bankers and management teams don’t like shares to trade below the offering price because it will be perceived as a failed offering. That scenario usually causes management to spend an inordinate amount of their time explaining why their business isn’t flawed just because their price dropped relative to its offering price.
    (Part 1)

    Sentiment: Strong Buy

  • tony_montello2003 tony_montello2003 Oct 29, 2014 10:10 AM Flag

    IPO Underwriters of the Week: October 13 – 17
    Posted on October 20, 2014 | Leave a comment
    Congratulations to the corporations and underwriters that worked with our transaction services team. Whether in-house, your-house or 100% virtual… click here to discover why we are the intelligent value for both traditional and confidential IPOs.
    ACTC on the list.
    Let it be written,
    Dr. Tony Montello.

    Sentiment: Strong Buy

  • tony_montello2003 tony_montello2003 Oct 29, 2014 12:34 AM Flag

    Thanks Mike, I look forward to the new video. I must say that I am completely appalled at Esekla, Doug D go 360 on ACTC. I guess blessed are those who have not seen and yet have believed." I say to all ACTC critics that don't see that all roads that lead to NASDAQ will reward those who are true longs 100 fold from here. OCATA new management is holding the royal flush close to their chest and will lay it down on the table in coming days before the ASM or after they land on NASDAQ. Riddle me this, there are 9 events that are bigger than ACTC Lancet publication yet to be announced!
    Let it be written,
    ACTC is gone, OCATA is coming,
    Dr. Tony Montello.

    Sentiment: Strong Buy

  • tony_montello2003 tony_montello2003 Oct 28, 2014 11:35 PM Flag

    Mike,
    Excellent post, I like your video with wine glass as well it brought some good laughs for me and my colleagues heavily invested in this medical history altering little regenerative company. I must say that I disagree with you about the butterfly metaphor because I truly believe this is the KRAKEN that will cause the desolation of big PHARMA in coming years if they don't partner with OCATA early enough. OCATA has a pipeline that will put lot of Big PHARMA companies out of business if they don't join the impending revolution of OCATA regenerative medicine one cure at a time!
    Let it be written,
    Dr. Tony Montello just left the building.)

    Sentiment: Strong Buy

  • tony_montello2003 tony_montello2003 Oct 26, 2014 11:35 PM Flag

    hschlauch,
    Excellent post, do you think big PHARMA is going to wait around for OCATA Re-IPO? or they are going to make a move? OCATA after raising the capital will be like a KRAKEN out of control it will vaporize big pharma multi billion dollar drugs one at a time! MM that are short ACTC shares I hope they don't cover till $50+ on NASDAQ!
    Let it be written,
    Dr. Tony Montello

    Sentiment: Strong Buy

  • tony_montello2003 tony_montello2003 Oct 26, 2014 3:40 PM Flag

    Clearly Road Show for RE IPO, Good Bye Otcbb, Hello NASDAQ global markets. Actc management executing flawlessly. I say we open over $30.00 on Nasdaq.
    Let it be written,
    Dr Tony Montello

    Sentiment: Strong Buy

  • REGN journey started getting interesting in last 5 years, before the chart had flat lined for years just like ACTC, than came the phase 2 for REGN and soon after that Big PHARMA partners. REGN had good efficacy when they started phase 2 for ELEYA for wet AMD but nowhere close to what OCATA's efficacy for AMD/SMD with RPE MA09 Therapy. I wrote here a month ago that right after the Publication ACTC/OCATA cure will be met with shock, disbelief and that's exactly what is happening, the medical world is not ready for a cure they are in total disbelief but the patients are and with twitter, Facebook generation they can't stop OCATA. Bush was able to stop ACTC but nobody will be able to stop OCATA because the cat is out of the bag. We will see in coming days the result of cohort 2A better vision patients and the results will wipe out all the critics forever. OCATA RPE cell therapy is 10 times bigger than REGN ELEYA wet AMD because of the market size of AMD. OCATA has to walk a fine line to keep the regulators happy and that's what they are doing say less do more. Trust me, my patience is being tested everyday but our reward of patience will be 100 fold from where ACTC PPS is sitting at right now because when the OCATA KRAKEN takes flight on NASDAQ it will be backed by billion dollar Institutional funds that control the markets.)
    Let it be written,
    Dr. Tony Montello just left the building.)

    Sentiment: Strong Buy

  • tony_montello2003 tony_montello2003 Oct 20, 2014 10:08 PM Flag

    ACTC has announced some very world changing innovations by releasing the Interim Top Line Data for their RPE MA09 Cell Therapy for AMD/SMD. I doubt any professional with good faith due diligence can dispute the data, especially when the data has been peer reviewed by world renowned medical journal LANCET. I believe that ACTC actions following the data release are posturing for best partnership deal as they portray to the world that they like to go at it alone and bring this multi billion dollar therapy to the market alone. ACTC news today of hiring a very seasoned Chief commercial Officer sends a signal to big PHARMA that they are ready to go at it alone unless there is a deal on terms favorable to ACTC. Mark my words every Big PHARMA that has a Ophthalmology program is aware of the LANCET publication of ACTC Interim Top line Data and pretty soon a bidding war is about to start, hold on to your shares tight the ball is in our court. Relax, Enjoy the ride I have seen this play out countless times...........
    Let the bidding war start,
    Dr. Tony Montello

    Sentiment: Strong Buy

SNSS
2.12+0.05(+2.42%)Nov 21 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.